

A Truncating Mutation in *SERPINB6* Is Associated with Autosomal-Recessive Nonsyndromic Sensorineural Hearing Loss

Aslı Sirmacı,^{1,2} Seyra Erbek,³ Justin Price,^{1,2} Mingqian Huang,⁴ Duygu Duman,⁵ F. Başak Cengiz,⁵ Güneş Bademci,^{1,2} Suna Tokgöz-Yılmaz,⁵ Burcu Hişmi,⁵ Hilal Özdağ,⁶ Banu Öztürk,⁷ Sevsen Kulaksızoğlu,⁸ Erkan Yıldırım,⁹ Haris Kokotas,¹⁰ Maria Grigoriadou,¹⁰ Michael B. Petersen,¹⁰ Hashem Shahin,¹¹ Moien Kanaan,¹¹ Mary-Claire King,¹² Zheng-Yi Chen,⁴ Susan H. Blanton,^{1,2} Xue Z. Liu,^{2,13} Stephan Zuchner,^{1,2} Nejat Akar,⁵ and Mustafa Tekin^{1,2,*}

More than 270 million people worldwide have hearing loss that affects normal communication. Although astonishing progress has been made in the identification of more than 50 genes for deafness during the past decade, the majority of deafness genes are yet to be identified. In this study, we mapped a previously unknown autosomal-recessive nonsyndromic sensorineural hearing loss locus (DFNB91) to chromosome 6p25 in a consanguineous Turkish family. The degree of hearing loss was moderate to severe in affected individuals. We subsequently identified a nonsense mutation (p.E245X) in *SERPINB6*, which is located within the linkage interval for DFNB91 and encodes for an intracellular protease inhibitor. The p.E245X mutation cosegregated in the family as a completely penetrant autosomal-recessive trait and was absent in 300 Turkish controls. The mRNA expression of *SERPINB6* was reduced and production of protein was absent in the peripheral leukocytes of homozygotes, suggesting that the hearing loss is due to loss of function of *SERPINB6*. We also demonstrated that *SERPINB6* was expressed primarily in the inner ear hair cells. We propose that *SERPINB6* plays an important role in the inner ear in the protection against leakage of lysosomal content during stress and that loss of this protection results in cell death and sensorineural hearing loss.

Genetic causes of hearing loss are estimated to account for 68% of cases in newborns and 55% of cases by the age of four.¹ Autosomal-recessive, dominant, and X-linked inheritance accounts for 77%, 22%, and 1% of the genetic deafness, respectively.² Most cases of genetic deafness fall into the category of sensorineural hearing loss and are caused by pathologies of the inner ear or auditory nerves; these can be identified with audiological investigations. Hearing loss can be classified into syndromic (20%–30%) and nonsyndromic (70%–80%) forms based on the presence or absence of distinctive clinical or laboratory features. More than 50 dominant and/or recessive genes for nonsyndromic sensorineural hearing loss have been identified and most of the 35 genes for the autosomal-recessive form were initially mapped in consanguineous families or population isolates.

During our studies on hereditary deafness, which were approved by Ankara University Ethics Committee (Turkey), by the IRB at the University of Miami (USA), and by the Ethics Committee of the Institute of Child Health, Athens (Greece), we ascertained a Turkish family, family 728, in which four children with sensorineural hearing loss were born to consanguineous parents. The father, whose parents were also first cousins, had sensori-

neural hearing loss as well (Figure 1A). Diagnosis of sensorineural hearing loss was established via standard audiometry. Audiograms of family 728 showed that the hearing loss was moderate to severe with some residual hearing in all affected individuals (Figure 1B). All affected members of the family had oral communication with partial help of lip reading. Individual 201, at 54 years old the eldest affected in the family, had the most severe hearing loss with more severe involvement of high frequencies. The youngest affected family member, 106, was 23 years old with hearing loss involving all frequencies. He self-reported that he started having more difficulties in hearing after age 20. A progressive nature of hearing loss was reported by affected individuals but has not been verified with audiograms. The age at the onset of hearing loss could not be precisely determined because previous audiograms were not available. The remainder of the examination was completely normal including normal anterior chamber and fundus of the eyes. Affected individuals did not have delays in gross motor development. Neither did they have balance problems, vertigo, dizziness, or spontaneous and positional nystagmus. Tandem walking was normal and Romberg test was negative. CT scans of the temporal

¹Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA; ²John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA; ³Department of Otorhinolaryngology, Baskent University School of Medicine, Ankara 06490, Turkey; ⁴Eaton-Peabody Laboratory, Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston 02114, USA; ⁵Division of Genetics, Department of Pediatrics, Ankara University School of Medicine, Ankara 06100, Turkey; ⁶Biotechnology Institute, Ankara University, Ankara 06100, Turkey; ⁷Department of Ophthalmology, Selcuk University Meram School of Medicine, Konya 42080, Turkey; ⁸Department of Biochemistry, Baskent University School of Medicine, Konya 42080, Turkey; ⁹Department of Radiodiagnosics, Baskent University School of Medicine, Konya 42080, Turkey; ¹⁰Department of Genetics, Institute of Child Health, 'Aghia Sophia' Children's Hospital, Athens 11527, Greece; ¹¹Department of Life Sciences, Bethlehem University, Bethlehem, Palestinian Authority; ¹²Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA; ¹³Department of Otorhinolaryngology, University of Miami, Miller School of Medicine, Miami, FL 33136, USA

*Correspondence: mtekin@med.miami.edu

DOI 10.1016/j.ajhg.2010.04.004. ©2010 by The American Society of Human Genetics. All rights reserved.




Figure 1. The DFNB91 Locus, Audiograms, and Molecular Studies in Family 728

(A) Haplotypes created with SNP markers show complete cosegregation of a locus at 6p25 (DFNB91) in family 728. (B) Audiograms of seven members of family 728. 301, 102, and 103 have heterozygous, 201, 101, 105, and 106 have homozygous p.E245X mutation in *SERPINB6*. (C) Electropherograms showing the p.E245X (c.733G>T) mutation in *SERPINB6*. (D) Relative quantity values of *SERPINB6* cDNA obtained from peripheral blood leukocytes of homozygotes and heterozygotes in family 728. Difference between homozygotes and heterozygotes is statistically significant ($p = 0.034$). (E) The western blotting results of *SERPINB6* in peripheral blood leukocytes in homozygous and heterozygous members of family 728. The 42 kDa protein is clearly visible in NIH/3T3, HeLa cells, and a healthy person with wild-type *SERPINB6*. A reduced *SERPINB6* band is visible in a heterozygote. The *SERPINB6* protein band is completely absent in homozygotes.

bone in two affected family members were normal as well. EKGs, liver and kidney function tests, serum electrolytes, urinalysis, CBC, and leukocyte subgroups were all within normal limits in affected subjects.

DNA was extracted from peripheral leukocytes of each member of family 728 via phenol chloroform method.

Two affected individuals (728-101 and 728-201) were pre-screened and found to be negative for mutations in *GJB2* (MIM 121011) via direct sequencing of both exons and for the m.1555A>G mutation in *MTRNR1* (MIM 561000) via an RFLP method via previously reported protocols.^{3,4} Genome-wide SNP genotyping was done in eight members

of family 728 (201, 301, 101, 102, 103, 104, 105, and 106) via Illumina 1M duo beadchips and assays (Illumina, CA). The DNA samples were processed according to Illumina procedures for processing of the Infinium II assay, the BeadChips were scanned on the Illumina BeadArray Reader, and data were extracted by the Illumina Beadstudio software (Illumina). Before analysis, overall sample call rate, gender consistency checks, relationship inference (via the Graphical Representation of Relationships program),⁵ and the Mendelian inconsistency rates were used for quality assessment. Genotypes were transferred into Excel files and sorted according to genomic positions along with all 35 previously identified autosomal-recessive nonsyndromic deafness genes. The cosegregation of the flanking genotypes for each gene was visually evaluated. None of the known deafness loci cosegregated with the phenotype, thereby excluding these as possible causes and suggesting that a mutation in a previously unknown deafness gene was responsible in this family. Copy number variants (CNVs) were assessed by determining the relative loss or gain of fluorescent signal intensity from SNP or CNV probes on the array via PennCNV program⁶ and no segregating CNVs were detected.

Regions of autozygosity from the SNP screen were first sought with PLINK.⁷ All five affected members of family 728 were concordant for homozygous SNP marker blocks that were larger than one megabase in five chromosomal locations (Table S1 available online). Haplotypes were constructed for homozygous genomic segments and their cosegregation with deafness was assessed visually. Only the homozygous block between 289,878 bp (rs7762811) and 3,908,468 bp (rs13205752) (total length was 3,618,590 bp) at 6p25 cosegregated with hearing loss in the family (Figure 1A) (NCBI Build 36.1; hg18). The other four large shared homozygous stretches in affected family members did not cosegregate with the phenotype and were not further analyzed. A genome-wide two-point linkage analysis was performed with SuperLink.⁸ Sixteen SNP markers on chromosomes 6, 8, 16, and 21 were detected with a LOD score of more than 3 (Table S2). Visual evaluation of haplotypes in these regions confirmed that the largest autozygous segment cosegregating with the phenotype was the same 3,618,590 bp region at 6p25. There were five other cosegregating segments on chromosomes 8, 16, and 21 with much smaller sizes ranging from 8,791 bp to 273,430 bp (Table S2). Before concentrating on the largest autozygous region on chromosome 6, the other five cosegregating regions were evaluated for their gene content with the UCSC genome browser. There were no known genes within the regions at chromosomes 16 and 21. The cosegregating segment on chromosome 8 was 14,852 bp long and partially included *MSRA* (MIM 601250). Sequencing of all six exons as well as intron-exon boundaries of this gene in two affected members of family 728 did not detect a mutation.

The only remaining autozygous segment that could contain a previously unrecognized deafness gene in family

728 was at 6p25. Multipoint linkage analysis of this segment was conducted with Fastlink⁹ assuming a fully penetrant autosomal-recessive disease, with a disease allele frequency of 0.0001. Both inbreeding loops were retained in the analysis. SNPs spanning the homozygous region were chosen for linkage analysis based on tagging and heterozygosity in the parents. Allele frequencies were obtained from the CEU HapMap. Linkage analysis detected a maximum lod score of 5.0 between recombinant markers rs7762811 and rs13205752 at 6p25 (Figure 1A). Examination of haplotypes between these two SNPs not included in the multipoint analysis did not identify any recombinations. This locus was designated as DFNB91 by the HUGO Nomenclature Committee.

The linkage interval at 6p25 included 24 known protein coding genes listed on the UCSC database (Figure S1). None of these genes have been previously reported to cause any forms of hearing loss in humans or in animals. The coding exons and intron-exon boundaries of all 24 genes were sequenced in family 728 (Figure S1 and Table S3). A homozygous nonsense mutation, p.E245X (c.733G>T) (according to GenBank accession number NM_004568.4), was identified in *SERPINB6* (MIM 173321) in all affected members of family 728 (Figure 1C). No other DNA sequence change in this gene was detected. This mutation removes 131 amino acids in the carboxy terminal of the protein including the reactive center loop. It completely cosegregated with deafness in family 728. The identified mutation was not found in 300 Turkish controls via an amplification refractory mutation detection system (ARMS) protocol that was shown to be sensitive and specific with DNA sequence analysis-proven homozygous, heterozygous, and wild-type samples (Table S3). One previously unreported intronic change and 21 previously reported SNPs were detected in other sequenced genes. None of these changes were predicted to have an effect on function (Table S4).

A premature stop codon was likely to activate nonsense-mediated mRNA decay response, thus leading to a decreased *SERPINB6* mRNA expression. *SERPINB6* was known to be expressed in white blood cells. Total RNA was isolated from peripheral blood samples of seven members of family 728 and cDNA was synthesized. The sequencing of *SERPINB6* in cDNA containing the point mutation with exonic primers detected the p.E245X (c.733G>T) mutation in both homozygotes and heterozygotes, showing that the identified mutation was present at the mRNA level. The quantitative expression analysis of *SERPINB6* was performed with TaqMan PCR assays in quadruplicate for each individual on cDNA samples via ABIPrism 7900 HT Sequence Detection system 2.3 (Applied Biosystems Inc., CA) (for methods, see Table S3). The mRNA expression was significantly reduced in homozygotes compared to those in heterozygotes (Figure 1D) ($p = 0.034$; Mann-Whitney U test), indicating that the premature stop codon destabilizes mRNA, leading to mRNA decay.

The protein expression of the mutant *SERPINB6* was evaluated in peripheral leukocytes of homozygotes and heterozygotes (for methods, see Table S3). The expected SERPINB6 band was not detected in homozygotes, whereas the 42 kDa protein was visible in a normal control and a heterozygote (Figure 1E). The truncated protein product of *SERPINB6* with the p.E245X mutation was estimated to be 27 kDa via Current Protocols database dna-rna-protein molecular weight calculator software. A truncated protein was not observed in heterozygotes or homozygotes, suggesting that the truncated protein is either not produced or rapidly degraded.

For identification of other families with *SERPINB6* mutations, the probands of a total of 256 unrelated multiplex families with autosomal-recessive nonsyndromic sensorineural hearing loss were screened. These families were from Turkey (202), Greece (26), and the USA (28). The vast majority of affected members of these families had severe to profound congenital or prelingual onset sensorineural hearing loss. Sequencing of all seven exons revealed seven additional previously unreported single-nucleotide changes (Table S5). However, these changes are unlikely to be the cause of phenotype because (1) they did not cosegregate with deafness in the families and (2) in silico analyses with PolyPhen and SIFT predicted that they do not affect protein function and are therefore likely to be benign. An additional 286 Palestinian probands from multiplex autosomal-recessive nonsyndromic deafness families were screened for the p.E245X mutation with a restriction fragment length polymorphism (RFLP) method because the mutation removes the recognition site of the *BsII* restriction enzyme (Table S3). None of the samples were found to be positive for the screened mutation.

Given the observed hearing loss in humans, immunostaining and in situ hybridization were used to identify the site for Serpinb6 expression in developing mouse inner ear. Immunohistochemistry was performed with developing mouse inner ear tissues according to the protocol as described before.¹⁰ In brief, frozen sections of the inner ear tissues were dried for 15 min at 37°C and rehydrated in 1×PBS for 5 min. Then, the sections were subjected to an antigen unmasking treatment via the Antigen Unmasking Solution (Vector Laboratories, UK) according to the manufacturer's protocol. The blocking, primary antibody and second primary antibody incubation followed the standard protocol. Antibodies used in the study are goat anti-SERPINB6 (human) (sc-21143, Santa Cruz Biotechnology, CA); rabbit anti-Myo7a (Proteus BioSciences Inc., CA), and rabbit anti-Ptprq (a gift from Dr. Guy Richardson, University of Sussex, UK). The secondary antibodies were anti-goat Alexa 594 and anti-rabbit Alexa 488 (Invitrogen Corporation, CA) for fluorescent labeling. Data visualization and acquisition were performed with a Zeiss Axio-scope 2 fluorescent microscope. A weak Serpinb6 signal was detected in E13.5 utricle sensory epithelium but not in hair cells (Figures 2A–2D). At E16.5, more prominent

Serpinb6 was detected in crista hair cells (Figures 2E–2H). Hair cell expression of Serpinb6 was sustained in postnatal mice (data not shown). In cochlea, Serpinb6 was detected in cochlear hair cells in embryo (Figures 2I–2L) and in hair cells and the greater epithelial ridge (GER) region in early postnatal age (Figures 2M–2P). In both cochlear and utricular hair cells, Serpinb6 was found in cytoplasm (Figures 2E and 2M). There are five mouse Serpinb6 orthologs including Serpinb6a, b, c, d, and e, and the human SERPINB6 antibody recognizes mouse Serpinb6a and Serpinb6c. Mouse Serpinb6a has the highest homology to human SERPINB6 with 75% identity, whereas Serpinb6c is 68% identical to SERPINB6. To further confirm immunohistochemistry results from the human SERPINB6 antibody study, we performed in situ hybridization with the mouse Serpinb6a antisense probe. The mouse Serpinb6a cDNA was purchased from Thermo Scientific Open Biosystems (clone ID: 5342439), and the preparation of riboprobes and in situ hybridization followed the protocol described.¹¹ The Serpinb6a in situ results matched that from immunostaining with weak expression in E18.5 and significantly increased expression in P6 GER and cochlear hair cells (Figures 2Q and 2S).

Proteases are important components of a number of physiological processes, including coagulation, cell migration, phagocytosis, fibrinolysis, cell-mediated cytotoxicity, complement fixation, and apoptosis. To avoid nonspecific tissue damage, protease activity is regulated by inhibitors, such as members of the serpin superfamily. Inhibitory serpins bind their target proteases irreversibly, via a conformational change that deforms the protease and stabilizes the serpin-protease complex.¹² Serpin dysfunction or deficiency is the underlying factor in a variety of human diseases, including emphysema, angioedema, thrombosis, and dementia^{13,14} because of uncontrolled tissue damage by different proteases.

In humans, the largest serpin clade (clade B) contains 13 intracellular proteins.¹³ Although their physiological roles remain largely unknown, there is evidence that they are involved in the regulation of cell growth, differentiation, and cytoprotection. A distinct subset of clade B serpins comprises *SERPINB1* (MIM 130135), *SERPINB6*, and *SERPINB9* (MIM 601799), which are encoded by a gene cluster on chromosome 6.¹⁵ SERPINB6 (also named placental thrombin inhibitor, PTI, cytoplasmic antiproteinase, and protease inhibitor-6) was discovered in 1993 in human placental tissue.¹⁶ Its reactive center is located at Arg-341 and Cys-342, and it lacks a classical N-terminal signal sequence, showing that it is not an extracellular protein.¹⁷ Intracellular serpins, Serpins b6, b9, and b1 in particular, have been implicated in cytoprotective roles. For example, Serpinb9 inhibits the cytotoxic lymphocyte protease granzyme B.^{18,19} Serpinb6 is a potent inhibitor of the monocyte/granulocyte protease cathepsin G, which is stored in azurophilic granules and then released into phagolysosomes or secreted during inflammation,²⁰ and kallikreins,²¹ which are stored in cytoplasmic storage vesicles




Figure 2. Detection of Serpinb6 in the Developing Mouse Inner Ear by Immunohistochemistry and In Situ Hybridization

(A–D) Weak Serpinb6 was detected in E13.5 utricular sensory epithelium. However, Serpinb6 was not in utricular hair cells, which were labeled with myo7a (B). Lines show examples of hair cells that are devoid of Serpinb6 (A).

(E–H) Distinct Serpinb6 was detected in E16.5 crista hair cells (lines).

(I–L) Weak Serpinb6 was detected in E16.5 cochlear hair cells. Multiple inner and outer hair cells were shown due to a section angle (J).

(M–P) Serpinb6 was upregulated in P6 inner and outer hair cells (IHC, OHC), with mainly cytoplasm distribution. Ptpqr labeled hair bundles (N)⁴⁰. In addition, Serpinb6 was detected in the GER at this stage.

(Q–T) In situ hybridization showed very weak Serpinb6a expression in E18.5 cochlear hair cells and GER (Q), whereas the expression was significantly increased in P6 cochlear hair cells and GER (S). Control sense probe did not produce any signal (R, T).

Abbreviations: Coch, cochlea; Cr, crista; Ut, utricle; anti-sen, antisense probe; sen, sense probe. Magnification: 40×.

analogous to leukocyte granules. Any proteases released into the interior of the cell during cellular stress would be rapidly inactivated by intracellular serpins. Although cells can tolerate and repair lysosomal ruptures to a certain degree, as the amount of damage increases, cells may undergo apoptosis or necrosis. A dramatic support for this model has recently been reported where a *C. elegans* intracellular serpin, *srp-6*, exhibited a prosurvival function

by blocking necrosis. Minutes after hypotonic shock, *srp-6* null animals underwent a catastrophic series of events culminating in lysosomal disruption, cytoplasmic proteolysis, and death. This “hypo-osmotic stress lethal” phenotype was dependent upon calpains and lysosomal cysteine peptidases, two in vitro targets of *srp-6*. By protecting against both the induction of and the lethal effects from lysosomal injury, *srp-6* also blocked death induced by

heat shock, oxidative stress, hypoxia, and cation channel hyperactivity.²²

To assess the effects of overexpression of wild-type and mutant *SERPINB6* under osmotic stress, we studied transiently transfected human cell lines and evaluated the integrity of the lysosomal content. For the evaluation of the lysosomal integrity, we used a pH-dependent marker of lysosomes, LysoTracker-red, in cultured cells as reported previously.²³ The lysates of HeLa cells were probed for *SERPINB6* with monoclonal antibody (SA-622, Enzo Life-Sciences, PA), which showed that HeLa cells expressed *SERPINB6* endogenously. Constructs encoding Serpinb6-GFP fusion protein were subcloned from an untagged Human cDNA clone (SC321547, OriGene Technologies, MD) via PCR amplification and TOPO cloning via the pcDNA3.1/NT-GFP-TOPO cloning kit (Invitrogen Corporation, CA). The primer sequences used for generating the constructs are available in Table S3. In brief, the *SERPINB6*-GFP-F primer was used in conjunction with the *SERPINB6*-WT-R or the *SERPINB6*-MUT-GFP-R to generate a PCR amplicon for either the wild-type or mutant constructs, respectively. The proper sized amplicon was selected for gel extraction and then cloned into the pcDNA3.1/NT-GFP-TOPO. Colonies were selected and screened via Sanger sequencing with Applied Biosystems BigDye Terminator Cycle Sequencing Kit (Applied Biosystems Inc., CA).

HeLa cells were transfected with the *SERPINB6*-WT-GFP, the *SERPINB6*-MUT-GFP, and the pcDNA3.1-Control-GFP expression vectors in 96-well BD Falcon plates (353948, BD Bioscience, CA) with Lipofectamine 2000 and incubated at 37°C with 5% CO₂. Twenty-four hours after transfection, cells were incubated in a 75 nM working concentration of LysoTracker Red 99-DND (Invitrogen Corporation) and then either continued to be cultured in PBS or introduced to osmotic shock by replacing the culture media with molecular biology grade water. After 5 min, plates were measured on Cytellect's adherent cell cytometer Celigo (Celigo Inc., CA). Three-channel, 8-bit stitched images were generated covering whole wells to identify the surface area and number of cells along with fluorescent intensities. We measured three channels: bright field, to count and locate cells; green, to measure number and intensity of the expressed recombinant protein; and red, to measure intensity of LysoTracker. Images were analyzed with the Celigo software (Celigo Inc.). The intensity of the red channel signal was averaged per each replicate in PBS and water. A Student's two-tailed t test was performed by comparing two histograms of intensity distributed over 35 bins from 0 to 255, representing the dynamic range at which intensity can be measured across an 8-bit image.

HeLa cells transfected with wild-type *SERPINB6* showed less reduction in red fluorescence (lysosomal content assessed through the maintenance of their lysosomal pH gradient and acidic environment) than that of the truncated mutant protein or the control GFP expression vector. Differences for the average intensities of LysoTracker

between PBS and water incubation were 43.23%, 65.48%, and 60.47% for *SERPINB6*-WT-GFP, *SERPINB6*-Mut-GFP, and control-GFP, respectively (Figure 3), with all shifts being found statistically significant with p values of 0.011, 0.00005, and 0.0001, respectively. The *SERPINB6*-Mut-GFP and control-GFP showed 44.4% and 39.0% more intensity decrease, respectively, in LysoTracker signal as compared to the *SERPINB6*-WT-GFP protein when incubated in water; p values are 0.003 and 0.024, respectively.

Further, we observed that cells incubated in PBS show discernable red structures representing lysosomes. When PBS was replaced with water, LysoTracker morphology changed from bright punctuate spots to red spots with a general pinkish hue in the cytosol (Figure 3). This shift can also be seen in the histogram distributions (Figures 3A–3C), which indicates that lysosomes cannot maintain their acidic environment, leading to leakage and disruption.²³ Observed changes in red fluorescence was roughly equivalent between the Control-GFP and the *SERPINB6* Mutant while disintegrity of lysosomes in cells from the overexpressed *SERPINB6*-WT constructs was significantly less (Figures 3A–3G). These results demonstrate that wild-type *SERPINB6* has a protective effect for lysosomal integrity in osmotic stress in a human cell line, similar to the results of a previous study for *srp-6* shown in *C. elegans*.²² Loss of this protective effect, as shown in our experiments with the truncated protein, is associated with increased lysosomal disintegrity. We also showed that the truncated protein is localized in the cytoplasm, similar to the wild-type *SERPINB6*, and did not have an additional adverse effect on lysosomal integrity. These results are consistent with the theory that the phenotype associated with the homozygous truncated *SERPINB6* is due to loss of function of the protein.

Given its increased expression in hair cells in the aging inner ear, it is highly plausible to envision a role for serpins in the inner ear cells, and particularly in hair cells, in the protection against various noxious stimuli including noise, ototoxic drugs, or trauma during aging process. These stimuli as well as normal physiological hearing processes may induce cellular stress, such as oxidative stress, that results in death of hair cells as individuals get older.²⁴ Leakage of lysosomal content resulting from various stress conditions is likely to occur in hair cells. To reduce hair cell damage and remain functional, *SERPINB6* may be required to counter the potentially cytotoxic components of leaking lysosomal proteases.

In conclusion, several lines of evidence supported the hypothesis that the identified *SERPINB6* mutation was responsible for hearing loss: (1) it completely cosegregated with hearing loss in a large family; (2) the identified mutation removed the functional domain of the *SERPINB6* protein, *SERPINB6* mRNA expression was reduced, and protein expression was absent in homozygotes; (3) the identified mutation was absent in 300 ethnically matched controls; and (4) *SERPINB6* was expressed in the inner ear, in particular in hair cells. The phenotype associated




Figure 3. The Effects of Transient Overexpression of SERPINB6 on Lysosomes in HeLa Cells

(A–C) Distribution of LysoTracker Red 99-DND Florescence in HeLa cells transfected with different GFP constructs. Distribution of the intensity range and frequency of LysoTracker-red was different in SERPIN-B-6-WT cells from both mutant and control cells after water treatment. Histograms show that most lysosomes lost their integrity in mutant and control cells, while some lysosomes remain less disrupted in SERPINB6-WT cells.

(D–G) Representative examples of images of wild-type and mutant SERPINB6-transfected HeLa cells. Green signal shows the overexpressed wild-type or mutant SERPINB6, which is localized in the cytoplasm. Red signal shows intact lysosomes. After osmotic stress, cells became round and lysosomes became indistinguishable with a general pinkish hue in the cytosol. However, this effect was less pronounced in cells where wild-type SERPINB6 is overexpressed.

(H) Averaged LysoTracker Intensities with standard deviation with PBS and water. Averaged LysoTracker intensity difference in WT SERPINB6-overexpressed cells is less than those in mutant SERPINB6-overexpressed and control cell lines ($p = 0.003$ and 0.024 , respectively, for the mutant and control cells).

with a *SERPINB6* mutation was moderate to severe, likely to be progressive sensorineural hearing loss. Absence of *SERPINB6* mutations in a large number of probands with congenital severe to profound hearing loss suggests that the typical phenotype caused by *SERPINB6* mutations is not congenital profound deafness. Mutations in recessive deafness genes usually cause severe to profound congenital or prelingual onset sensorineural hearing loss. Nevertheless, biallelic mutations in *LOXHD1* (MIM 613072), *MYO3A* (MIM 606808), and *PJVK* (MIM 610219) have been reported to cause progressive sensorineural hearing loss, suggesting that age-dependent hair cell failure is a common mechanism for progressive autosomal-recessive sensorineural hearing loss.^{25–27} The loss of function of an intracellular protease inhibitor, SERPINB6, resulting from a homozygous truncating mutation provides a highly plausible model for age-dependent hair cell failure.

Supplemental Data

Supplemental Data include one figure and five tables and can be found with this article online at <http://www.cell.com/AJHG>.

Acknowledgments

We are thankful to all participating families. We thank Professor Phillip I. Bird from Monash University, Australia, for helpful suggestions and critical reading of the manuscript. This study was partially supported by The Scientific & Technological Research Council of Turkey Grants (105S464 and 108S045), funds from the University of Miami to M.T., NIH R01 DC006908 to Z.-Y.C., National Natural Science Foundation of China to Z.-Y.C. (30728030), the Federick and Ines Yeatts inner ear hair cell regeneration fellowship to M.H., NIH R01 DC005575 to X.Z.L., and a grant from Oticon Fonden, Denmark, to M.B.P.

Received: February 15, 2010

Revised: April 6, 2010

Accepted: April 9, 2010

Published online: May 6, 2010

Web Resources

The URLs for data presented herein are as follows:

Current Protocols, <http://www.currentprotocols.com/tools/dnarnaprotein-molecular-weight-calculator>

Hereditary Hearing Loss Homepage, <http://webh01.ua.ac.be/hhh/>
National Institutes of Health (NIH) HapMap-CEU, http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?pop=1409
Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/>
Plink, <http://pngu.mgh.harvard.edu/purcell/plink>
PolyPhen, <http://genetics.bwh.harvard.edu/pph/>
SIFT, <http://sift.jcvi.org/>
UCSC Genome Browser, <http://genome.ucsc.edu>

References

1. Morton, C.C., and Nance, W.E. (2006). Newborn hearing screening—A silent revolution. *N. Engl. J. Med.* *354*, 2151–2164.
2. Morton, N.E. (1991). Genetic epidemiology of hearing impairment. *Ann. N Y Acad. Sci.* *630*, 16–31.
3. Tekin, M., Duman, T., Bogoclu, G., Incesulu, A., Comak, E., Fitoz, S., Yilmaz, E., Ilhan, I., and Akar, N. (2003). Frequency of mtDNA A1555G and A7445G mutations among children with prelingual deafness in Turkey. *Eur. J. Pediatr.* *162*, 154–158.
4. Tekin, M., and Arici, Z.S. (2007). Genetic epidemiological studies of congenital/prelingual deafness in turkey: Population structure and mating type are major determinants of mutation identification. *Am. J. Med. Genet. A.* *143A*, 1583–1591.
5. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R. (2001). GRR: Graphical representation of relationship errors. *Bioinformatics* *17*, 742–743.
6. Wang, K., Li, M., Hadley, D., Liu, R., Glessner, J., Grant, S.F., Hakonarson, H., and Bucan, M. (2007). PennCNV: An integrated hidden markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* *17*, 1665–1674.
7. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). PLINK: A toolset for whole-genome association and population-based linkage analysis. *Am. J. Hum. Genet.* *81*, 559–575.
8. Fishelson, M., and Geiger, D. (2002). Exact genetic linkage computations for general pedigrees. *Bioinformatics* *18* (Suppl 1), S189–S198.
9. Schäffer, A.A. (1996). Faster linkage analysis computations for pedigrees with loops or unused alleles. *Hum. Hered.* *46*, 226–235.
10. Sage, C., Huang, M., Vollrath, M.A., Brown, M.C., Hinds, P.W., Corey, D.P., Vetter, D.E., and Chen, Z.Y. (2006). Essential role of retinoblastoma protein in mammalian hair cell development and hearing. *Proc. Natl. Acad. Sci. USA* *103*, 7345–7350.
11. Huang, M., Sage, C., Li, H., Xiang, M., Heller, S., and Chen, Z.Y. (2008). Diverse expression patterns of LIM-homeodomain transcription factors (LIM-HDs) in mammalian inner ear development. *Dev. Dyn.* *237*, 3305–3312.
12. Huntington, J.A., Read, R.A., and Carrell, R.W. (2000). Structure of a serpin-protease complex shows inhibition by deformation. *Nature* *407*, 923–926.
13. Silverman, G.A., Bird, P.I., Carrell, R.W., Church, F.C., Coughlin, P.B., Gettins, P.G.W., Irving, J.A., Lomas, D.A., Luke, C.J., Moyer, R.W., et al. (2001). The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. *J. Biol. Chem.* *276*, 33293–33296.
14. Stein, P.E., and Carrell, R.W. (1995). What do dysfunctional serpins tell us about molecular mobility and disease? *Nat. Struct. Biol.* *2*, 96–113.
15. Scott, F.L., Eyre, H.J., Lioumi, M., Ragoussis, J., Irving, J.A., Sutherland, G.A., and Bird, P.I. (1999). Human ovalbumin serpin evolution: phylogenetic analysis, gene organization, and identification of new PI-8-related genes suggest that two interchromosomal and several intrachromosomal duplications generated the gene clusters at 18q21-q23 and 6p25. *Genomics* *62*, 490–499.
16. Coughlin, P.B., Tetaz, T., and Salem, H.H. (1993). Identification and purification of a novel serine proteinase inhibitor. *J. Biol. Chem.* *268*, 9541–9547.
17. Scott, F.L., Coughlin, P.B., Bird, C., Cerruti, L., Hayman, J.A., and Bird, P. (1996). Proteinase inhibitor 6 cannot be secreted, which suggests it is a new type of cellular serpin. *J. Biol. Chem.* *271*, 1605–1612.
18. Bird, C.H., Sutton, V.R., Sun, J., Hirst, C.E., Novak, A., Trapani, J.A., and Bird, P.I. (1998). Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. *Mol. Cell. Biol.* *18*, 6387–6398.
19. Hirst, C.E., Buzza, M.S., Bird, C.H., Warren, H.S., Cameron, P.U., Zhang, M., Ashton-Rickhardt, P.G., and Bird, P.I. (2003). The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. *J. Immunol.* *170*, 805–815.
20. Scott, F.L., Hirst, C.E., Sun, J., Bottomley, S.P., Bird, C.H., and Bird, P.I. (1999). The intracellular serpin proteinase inhibitor 6 (PI-6) is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule proteinase, cathepsin G. *Blood* *93*, 2089–2097.
21. Scott, F.L., Sun, J., Whisstock, J.C., Kato, K., and Bird, P.I. (2007). SerpinB6 is an inhibitor of kallikrein-8 in keratinocytes. *J. Biochem.* *142*, 435–442.
22. Luke, C.J., Pak, S.C., Askew, Y.S., Naviglia, T.L., Askew, D.J., Nobar, S.M., Vetica, A.C., Long, O.S., Watkins, S.C., Stolz, D.B., et al. (2007). An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury. *Cell* *130*, 1108–1119.
23. Zheng, J., Yan, T., Feng, Y., and Zhai, Q. (2010). Involvement of lysosomes in the early stages of axon degeneration. *Neurochem. Int.* *56*, 516–521.
24. Van De Water, T.R., Lallemand, F., Eshraghi, A.A., Ahsan, S., He, J., Guzman, J., Polak, M., Malgrange, B., Lefebvre, P.P., Staecker, H., et al. (2004). Caspases, the enemy within, and their role in oxidative stress-induced apoptosis of inner ear sensory cells. *Otol. Neurotol.* *25*, 627–632.
25. Grillet, N., Schwander, M., Hildebrand, M.S., Sczaniecka, A., Kolatkar, A., Velasco, J., Webster, J.A., Kahrizi, K., Najmabadi, H., Kimberling, W.J., et al. (2009). Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans. *Am. J. Hum. Genet.* *85*, 328–337.
26. Walsh, T., Walsh, V., Vreugde, S., Hertzano, R., Shahin, H., Haika, S., Lee, M.K., Kanaan, M., King, M.C., and Avraham, K.B. (2002). From flies' eyes to our ears: mutations in a human class III myosin cause progressive nonsyndromic hearing loss DFNB30. *Proc. Natl. Acad. Sci. USA* *99*, 7518–7523.
27. Delmaghani, S., del Castillo, F.J., Michel, V., Leibovici, M., Aghaie, A., Ron, U., Van Laer, L., Ben-Tal, N., Van Camp, G., Weil, D., et al. (2006). Mutations in the gene encoding pejvakin, a newly identified protein of the afferent auditory pathway, cause DFNB59 auditory neuropathy. *Nat. Genet.* *38*, 770–778.